| Document |
Document Title |
|
WO/2013/066106 |
The present invention relates to a method for preparaing a conjugate of a physiologically active polypeptide and a non-peptide polymer by linking physiologically active polypeptide with non-peptide polymer through a covalent bond using a...
|
|
WO/2013/067509 |
Methods and devices for purification of different cell components from the same sample are provided.
|
|
WO/2013/065782 |
The invention provides a protein-immobilizing solid phase and a polynucleotide-immobilizing solid phase that make it possible to recover nucleic acid efficiently from the solid phase, and an efficient nucleic acid recovery method. In one...
|
|
WO/2013/062105 |
Provided is an affinity carrier having a low pressure loss and a high binding capacity, even when the linear flow rate of a solution passing through the carrier is fast. Also provided is a silica spherical body having (a) according to la...
|
|
WO/2013/056377 |
The present invention provides citrullinated 14-3-3η peptides and antibodies thereto and methods of using same to evaluate arthritic conditions such as rheumatoid arthritis.
|
|
WO/2013/039190 |
The purpose of the present invention is to provide a polypeptide-containing polymer that can be used to manufacture an antimicrobial fiber. The purpose of the present invention is also to provide a method for polypeptide immobilization o...
|
|
WO/2013/038158 |
The disclosure relates to a magnetic particle comprising: a ligand that specifically binds an intracellular antigen, a cell membrane penetrating cationic peptide and a peptide comprising an amino acid sequence that is adapted to interact...
|
|
WO/2013/033838 |
Liposomal formulations of cationic peptides and anionic liposomes are provided. The liposomal formulations comprise a diagnostic or therapeutic cationic peptide associated with liposomes comprising one or more anionic lipids. Methods of ...
|
|
WO/2013/029180 |
It is provided PACE4 inhibitors and their uses for treating infection, cancer. Particularly, it is provided a method or use for the treatment of a cancer in a subject, comprising administering to the subject a therapeutically effective a...
|
|
WO/2013/029472 |
Provided is a composition for extracting unrelated circulating nucleated cells from the peripheral blood of a diseased animal model, comprising the composition kit. The composition consists of the following ingredients: buffer solution, ...
|
|
WO/2013/033359 |
Disclosed are devices that comprise a protein, such as an antibody, placed into electronic communication with a semiconductor material, such as a carbon nanotube. The devices are useful in assessing the presence or concentration of analy...
|
|
WO/2013/029182 |
It is provided furin inhibitors and their uses for treating pathogen infection. Particularly, it is provided a method or use for the treatment of a pathogen infection, in a subject, comprising administering to the subject a therapeutical...
|
|
WO/2013/027796 |
Provided is a peptide capable of binding to human IgG specifically or selectively. A peptide characterized by comprising an amino acid sequence represented by formula (I): (X1-3)-C-(X2)-H-R-G-(Xaa1)-L-V-W-C-(X1-3) (wherein Xs independent...
|
|
WO/2013/025052 |
The present invention relates to a bioactive carbon nanotube composite functionalized with a β-sheet polypeptide block copolymer which shows excellent water dispersion, and has biological activity so as to be used as a stimulus-reactive...
|
|
WO/2013/020079 |
Conjugates of an IL-1 1 moiety and one or more nonpeptidic, water-soluble polymers are provided. Typically, the nonpeptidic, water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are c...
|
|
WO/2013/018880 |
The purpose of the present invention is: to provide an excellent protein which is further reduced in the binding property to an Fc region of an immunoglobulin and/or the binding property to an Fab region of the immunoglobulin in a weakly...
|
|
WO/2013/010225 |
The present invention relates to enzymes capable of hydrolysing organophosphate (OP) molecules. In particular, the invention relates to variants of the OpdA enzyme from Agrobacterium that display improved activity when compared to the na...
|
|
WO/2013/010225 |
The present invention relates to enzymes capable of hydrolysing organophosphate (OP) molecules. In particular, the invention relates to variants of the OpdA enzyme from Agrobacterium that display improved activity when compared to the na...
|
|
WO/2013/009690 |
The present invention is directed to C-type lectin-like molecule-1 (CLL1) specific ligand peptides, comprising the amino acid motif LR(S/T), and methods of their use, e.g., for imaging detection for diagnosis of leukemia and the presence...
|
|
WO/2013/002449 |
Disclosed are an epitope specific to hepatitis B virus (HBV) and use thereof. The disclosed epitope is a conservative position on which mutagenesis does not occur and, therefore, a composition including an antibody to the foregoing epito...
|
|
WO/2012/177775 |
The invention provides methods for delivery of payloads to targets in samples using non-sterically hindered complexes. The invention further provides reagents and kits for practicing the methods of the invention. The invention also provi...
|
|
WO/2012/172346 |
A method for treating a respiratory conditions comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a ...
|
|
WO/2012/172339 |
A method for treating inflammatory arthritis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a ch...
|
|
WO/2012/173422 |
The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-p...
|
|
WO/2012/172343 |
A method for treating primary sclerosing cholangitis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding...
|
|
WO/2012/172337 |
A method for treating cardiovascular disease comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a ch...
|
|
WO/2012/172343 |
A method for treating primary sclerosing cholangitis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding...
|
|
WO/2012/172342 |
A method for treating multiple sclerosis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemok...
|
|
WO/2012/172342 |
A method for treating multiple sclerosis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemok...
|
|
WO/2012/171429 |
Disclosed are a polyethylene glycol-interferon conjugate, a preparation method thereof, and a pharmaceutical composition containing a therapeutically effective amount of the interferon conjugate and use thereof in the preparation of anti...
|
|
WO/2012/172346 |
A method for treating a respiratory conditions comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a ...
|
|
WO/2012/172345 |
A method for treating an allergic condition comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent capable of specifically binding to a chemokine rece...
|
|
WO/2012/172347 |
A method of diagnosing, monitoring progression of, or monitoring treatment of inflammatory bowel disease comprises determining the levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 in a sample o...
|
|
WO/2012/173422 |
The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-p...
|
|
WO/2012/172337 |
A method for treating cardiovascular disease comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a ch...
|
|
WO/2012/172340 |
A method for treating mental disorders such as schizophrenia, depression and bipolar disorder comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent c...
|
|
WO/2012/172345 |
A method for treating an allergic condition comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent capable of specifically binding to a chemokine rece...
|
|
WO/2012/172347 |
A method of diagnosing, monitoring progression of, or monitoring treatment of inflammatory bowel disease comprises determining the levels of CD14+HLA-DRhi monocytes or monocytes expressing CCR7 or CCR9 or both CCR7 and CCR9 in a sample o...
|
|
WO/2012/172340 |
A method for treating mental disorders such as schizophrenia, depression and bipolar disorder comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent c...
|
|
WO/2012/172336 |
A method for treating inflammatory skin disease comprises applying peripheral blood from a patient to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine ...
|
|
WO/2012/172344 |
A method for treating sepsis and/or respiratory distress syndrome (RDS) comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of s...
|
|
WO/2012/172344 |
A method for treating sepsis and/or respiratory distress syndrome (RDS) comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of s...
|
|
WO/2012/172339 |
A method for treating inflammatory arthritis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a ch...
|
|
WO/2012/172336 |
A method for treating inflammatory skin disease comprises applying peripheral blood from a patient to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine ...
|
|
WO/2012/159171 |
The present invention relates to complexes of silica-containing materials and peptide linkers for the capture of biological and chemical entities. In particular, the present invention relates to the use of complexes of silica-containing ...
|
|
WO/2012/159170 |
The present invention relates to methods of capturing biological and chemical entities indirectly or directly bound to a peptide linker. In particular, the present invention relates to the use of silica-containing materials to capture bi...
|
|
WO/2012/157339 |
This growth factor anchoring type bone graft material is characterized in that growth factor containing collagen-binding sites, which contains growth factor receptor agonist peptides and collagen-binding peptides, is bonded to a bone gra...
|
|
WO/2012/158445 |
The invention relates to methods for the temporal administration of EDA agonists, in particular EDI200, which correlate to optimal therapeutic response windows required for the formation of any EDA-dependent structures such as ectodermal...
|
|
WO/2012/154735 |
The present compositions and methods relate to a thermostable carbonic anhydrases, polynucleotides encoding the carbonic anhydrase, and methods of make and/or use thereof. Formulations containing the carbonic anhydrase are suitable for u...
|
|
WO/2012/154735 |
The present compositions and methods relate to a thermostable carbonic anhydrases, polynucleotides encoding the carbonic anhydrase, and methods of make and/or use thereof. Formulations containing the carbonic anhydrase are suitable for u...
|
